SEC Form S-8 filed by Spero Therapeutics Inc.
As filed with the Securities and Exchange Commission on August 12, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SPERO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-4590683 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts |
02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
SPERO THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN, AS AMENDED
(Full title of the plan)
Esther Rajavelu, President, Chief Executive Officer, Chief Financial Officer and Treasurer
Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
(Name and address of agent of service)
(857) 242-1600
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This registration statement registers an aggregate of 3,000,000 additional shares of common stock of Spero Therapeutics, Inc. (the “Registrant”) reserved under the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (the “2017 Plan”), representing an increase of 3,000,000 shares reserved under the 2017 Plan effective June 12, 2025. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 relating to the 2017 Plan has previously been filed and is effective. This registration statement incorporates by reference the contents of (i) the registration statement on Form S-8 (File No. 333-222060), filed with the Securities and Exchange Commission on December 14, 2017 by the Registrant, (ii) the registration statement on Form S-8 (File No. 333-230281), filed with the Securities and Exchange Commission on March 14, 2019 by the Registrant, (iii) the registration statement on Form S-8 (File No. 333-237283), filed with the Securities and Exchange Commission on March 19, 2020 by the Registrant, (iv) the registration statement on Form S-8 (File No. 333-254173), filed with the Securities and Exchange Commission on March 11, 2021 by the Registrant, (v) the registration statement on Form S-8 (File No. 333-259662), filed with the Securities and Exchange Commission on September 20, 2021 by the Registrant, (vi) the registration statement on Form S-8 (File No. 333-268344), filed with the Securities and Exchange Commission on November 14, 2022 by the Registrant, (vii) the registration statement on Form S-8 (File No. 333-275514), filed with the Securities and Exchange Commission on November 13, 2023 by the Registrant, and (viii) the registration statement on Form S-8 (File No. 333-281245), filed with the Securities and Exchange Commission on August 5, 2024 by the Registrant, in each case, except for Item 8, Exhibits.
Item 8. Exhibits.
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on August 12, 2025.
SPERO THERAPEUTICS, INC. | ||
By: | /s/ Esther Rajavelu | |
Esther Rajavelu | ||
President, Chief Executive Officer, Chief Financial Officer and Treasurer |
POWER OF ATTORNEY AND SIGNATURES
Each person whose signature appears below constitutes and appoints Esther Rajavelu and Timothy Keutzer, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Spero Therapeutics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Esther Rajavelu Esther Rajavelu |
President, Chief Executive Officer, Chief Financial Officer and Treasurer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) |
August 12, 2025 | ||
/s/ Frank E. Thomas Frank E. Thomas |
Chairman | August 12, 2025 | ||
/s/ Milind Deshpande, Ph.D. Milind Deshpande, Ph.D. |
Director | August 12, 2025 | ||
/s/ Scott Jackson Scott Jackson |
Director | August 12, 2025 | ||
/s/ Ankit Mahadevia, M.D. Ankit Mahadevia, M.D. |
Director | August 12, 2025 | ||
/s/ John C. Pottage, M.D. John C. Pottage, M.D. |
Director | August 12, 2025 | ||
/s/ Cynthia Smith Cynthia Smith |
Director | August 12, 2025 | ||
/s/ Kathleen Tregoning Kathleen Tregoning |
Director | August 12, 2025 | ||
/s/ Patrick Vink, M.D. Patrick Vink, M.D. |
Director | August 12, 2025 |